Michael Lawless1,2, Aldo Martinez3, Thomas Kohnen4
Purpose: To determine the Visual Acuity and Binoc- ular Defocus Curve outcomes of a novel trifocal lens, the AcrySof IQ PanOptix IOL at 12 months post- operative.
Method: A prospective, single arm, non-random- ized, multi-centre study (17 sites) was conducted involving the bilateral implantation of AcrySof IQ PanOptix Presbyopia Correcting IOL in 151 subjects. Binocular Uncorrected Distance VA (4 m), Binocular Distance Corrected intermediate VA (60cm & 80cm), Binocular Uncorrected near VA (40 cm) and Binocu- lar defocus curves were evaluated under photopic lighting conditions.
Results: A total of 145 subjects (38% M: 62% F) with a mean age of 68.9 9.3 years were implanted with the AcrySof IQ PanOptix IOL bilaterally and followed up for 1 year (330-420 days) . At 1 year post-op, the mean SD (logMAR) UDVA was 0.02 0.11; mean BDCIVA was 0.04 0.12 and 0.08
0.14 at 60cm and 80cm, respectively. Mean SD UNVA was 0.07 0.11. At 6-months follow up, the mean Defocus curve VA from 0.00D to -3.00D ran- ged from 0.1 to 0.0 logMAR. Average VA at distance (0.00D), intermediate (-1.50D) and near (-2.50D) was 0.0 0.1D, 0.0 0.1D and 0.1 0.1D, respectively.
Conclusion: The results from this study show very good visual performance (VA better or equal to 20/25) of the AcrySof IQ PanOptix IOL in both uncorrected and corrected conditions across the whole range of distances and defocus.
COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED FOLLOWING A ?TREAT AND EXTEND? PROTOCOL: EFFICACY VARIABLES FROM THE PRE-SPECIFIED 12- MONTH INTERIM ANALYSIS OF THE RIVAL STUDY